Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 3;8(8):102579.
doi: 10.1016/j.rpth.2024.102579. eCollection 2024 Nov.

Complement-mediated hemolytic uremic syndrome associated with postpartum hemorrhage: case series and systematic review of individual participant data

Anna Gurevich-Shapiro  1   2   3 , Sharon Orbach-Zinger  3   4 , Avi Leader  3   5 , Galia Stemer  6 , Arnon Wiznitzer  3   7 , Pierre Singer  3   8 , Miriam Davidovits  3   9 , Michael Shapiro  3   10 , Eva N Hamulyák  11 , Pia Raanani  3   5 , Galia Spectre  3   5
Affiliations

Complement-mediated hemolytic uremic syndrome associated with postpartum hemorrhage: case series and systematic review of individual participant data

Anna Gurevich-Shapiro et al. Res Pract Thromb Haemost. .

Abstract

Background: Postpartum hemorrhage is considered a risk factor for pregnancy-associated complement-mediated hemolytic uremic syndrome (CM-HUS; previously known as atypical hemolytic uremic syndrome) but has not been systematically studied.

Objectives: To systematically examine the role of postpartum hemorrhage in precipitating CM-HUS and to describe the characteristics of postpartum hemorrhage-associated CM-HUS, its prognosis and recommended management.

Methods: A systematic review of individual participant data from case series and reports in addition to a case series from our institution. Search terms were "thrombotic microangiopathy," "atypical hemolytic uremic syndrome," and "complement mediated" combined with "pregnancy," "postpartum," and/or "postpartum hemorrhage". Cases of thrombotic microangiopathy other than CM-HUS were excluded. Outcomes were clinical and laboratory characteristics of postpartum hemorrhage-associated CM-HUS, treatment, and outcomes.

Results: Thirty-three studies comprising 48 women with postpartum hemorrhage-associated CM-HUS and 3 patients from our institution were included in the study. Most women presented at term (28/45; 62%), delivered by cesarean section (21/41; 51%), and had pregnancy complications, mainly preeclampsia (16/51; 31%) or fetal demise (9/51; 18%). Hematological and renal abnormalities usually appeared within the first 24 hours postdelivery. The median platelet count was 46 × 109/L (IQR, 26-72), and the median maximal lactate dehydrogenase was 2638 U/L (IQR, 1620-3588). Renal function normalized in 20/23 (87%) women treated with C5 inhibitors with or without plasma exchange; in 7/11 (63%) women treated with plasma exchange alone, but only in 3/17 (18%) patients treated with supportive care. Patients treated with C5 inhibitors and/or plasma exchange achieved significantly better renal outcomes compared with supportive care alone (P < .001).

Conclusion: CM-HUS is a rare complication following postpartum hemorrhage and occurs mainly in women with preeclampsia and/or following cesarean section. Patients treated with C5 inhibitors and/or plasma exchange had a better renal prognosis compared with patients who received supportive treatment alone.

Keywords: Complement C5 inhibitors; Parturition; acute kidney injury; atypical hemolytic uremic syndrome; postpartum hemorrhage; postpartum period; pregnancy; pregnancy complications; thrombotic microangiopathies; treatment outcome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study selection flowchart. CM-HUS, complement-mediated hemolytic uremic syndrome; TMA, thrombotic microangiopathy; PPH, postpartum hemorrhage.
Figure 2
Figure 2
Patient outcomes according to treatment group.
See this image and copyright information in PMC

References

    1. Huerta A., Arjona E., Portoles J., Lopez-Sanchez P., Rabasco C., Espinosa M., et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2018;93:450–459. - PubMed
    1. Fakhouri F., Roumenina L., Provot F., Sallée M., Caillard S., Couzi L., et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21:859–867. - PMC - PubMed
    1. George J.N., Nester C.M., McIntosh J.J. Syndromes of thrombotic microangiopathy associated with pregnancy. Hematol Am Soc Hematol Educ Program. 2015;2015:644–648. - PubMed
    1. Adamski J. Thrombotic microangiopathy and indications for therapeutic plasma exchange. Hematol Am Soc Hematol Educ Program. 2014;2014:444–449. - PubMed
    1. Rosen M., Brauer K.I., Alperin J.B., Hankins G.D., Saade G. Postpartum hemorrhagic shock resulting in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. J Matern Fetal Neonatal Med. 2003;13:208–210. - PubMed

LinkOut - more resources